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dWinnie the Pooh (1)
In daily practice, we are confronted with a dilemma: what to
do if we ﬁnd a relevant paravalvular leak (PVL) after
transcatheter aortic valve replacement (TAVR): Should we
optimize the hemodynamic result by post-dilating the valve
prosthesis? Or should we accept the PVL? Are we willing
to increase the procedural risk in order to reduce potential
long-term sequelae? Balloon post-dilation (PD) is techni-
cally simple and effective in many occasions. Therefore, it
has been frequently adopted as ﬁrst-line therapy of PVL
to reduce the degree of residual aortic regurgitation (AR).
However, there is a scarcity of data to support this strategy,
and many issues remain controversial: How relevant is a
PVL? What is its real clinical consequence? What is the
efﬁcacy of PD? What is the risk of PD?See page 781The PARTNER (Placement of AoRTic TraNscathetER
Valves) trial (2,3) suggested residual AR following transcatheter
aortic valve implantation to be associated with a high risk
of premature death. This is in contrast with the natural
history of AR, which is a benign disease unless
it progresses to a severe degree. Turina et al. (4) in 1987
reported in a cohort of 80 patients with isolated AR
undergoing right and left heart catheterization that all
patients with moderate AR were still alive after 4 years,ublished in JACC: Cardiovascular Interventions reﬂect the views of the
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.and 10-year survival was as high as 79%, irrespective of
symptom status.
After surgical aortic valve replacement, the incidence of
PVLs is usually below 1% and is typically mild at most.
PVLs after surgical aortic valve replacement showed a
benign course up to 5 years (5), and do not affect long-term
outcome (6).
By contrast, PVL after TAVR is a rather frequent ﬁnding,
with an incidence of moderate or severe PVLs of about
12% (2,3).
Interestingly, although the hemodynamic consequences
remain the same as in natural AR or PVL after surgical valve
replacement, it seems that we are dealing with an different
entity affecting outcome differently, and asking for different
measures.
In AR after TAVR, decision making can be challenging
because of a variety of issues: the difﬁculty to properly
diagnose and quantify PVLs, the potential for spontaneous
reduction of AR in the short term without any intervention
(e.g., with self-expanding devices [7]), and the risk–beneﬁt
analysis in an individual patient.
Several factors will inﬂuence our decision whether to
post-dilate after TAVR or not, such as the severity of
the leak, the mechanism of PVL (low-implant, mismatch,
underinﬂation, calciﬁcation, etc.), and the patient’s indi-
vidual risk for post-dilation (PD). The individual risk of
stroke or annular rupture that is due to PD depends on
the severity of valvular calciﬁcation (in particular on the
amount of calciﬁcation in the left ventricular outﬂow tract)
and on the amount of prosthesis oversizing (8). To balance
the risk, we need to know the beneﬁt of an intervention.
The main question, therefore, remains whether reduc-
tion of PVL will indeed translate into better clinical
outcome. And more speciﬁcally: Is this the case even for
mild or moderate PVLs? Current data are somewhat
conﬂicting (3,7).
In this issue of JACC: Cardiovascular Interventions, the
data of Hahn et al. (9) provide us very valuable answers
to many important questions. Hahn et al. (9) assessed the
outcome of 2,135 patients, whereof 261 underwent PD of
their transcatheter valve, and 1,874 did not undergo PD.
That the clinical setting inﬂuences operators’ willingness
to post-dilate is reﬂected by the fact that inoperable patients
underwent PD less frequently than high-risk patients.
Importantly, Hahn et al. (9) suggest that PD, in fact, can
improve prognosis: whereas patients that underwent PD
after valve implantation had overall worse 1-year outcomes
(survival or stroke), in the subgroup of patients where PVL
was virtually eliminated by PD (n ¼ 102), 1-year outcome
was not different as compared with patients without PVL
after valve deployment. It, therefore, seems that successful
PD indeed improves prognosisdbut a selection bias cannot
be ruled out (e.g., that healthier patients are better
responding to PD).
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791Residual moderate and severe PVLs were predictors of
1-year mortality and the combined endpoint of mortality
and stroke. This ﬁnding, in line with other data, suggests
that moderate PVL itself negatively affects outcome, unlike
what we know from native aortic valve regurgitation.
Another important ﬁnding from the Hahn et al. study (9)
is that PD is not associated with early valve degeneration,
despite the extra stress on the valve leaﬂets during multiple
balloon inﬂations.
The bad news from Hahn’s data are, however, that PD
can indeed cause harm: there were signiﬁcantly more strokes
within 7 days, with a numerical doubling of the stroke rate in
the ﬁrst 7 days in the group of patients undergoing PD
(although at low absolute numbers).
Is this stroke risk due to the PD itself, or is it related to
patient bias? The issue remains unanswered. A calcium
score analysis would have helped to rule out a potential bias
from more severe baseline calciﬁcation in patients under-
going PD, therefore implying a higher embolic and overall
cardiovascular risk.
The decision whether to post-dilate or not was left at
the discretion of the operator. The majority of patients
comprised patients from the nonrandomized continuous
access registry, thus, they were inoperable patients. This may
explain why a rather large proportion of patients were left
with moderate or severe PVL (8% in the patients without
PD and 12% in the group with PD). This ﬁnding asks for
technical solutions: larger valve sizes that allow for more
generous oversizing and new valve technologies that reduce
the incidence of PVLsdsuch as there are already on the
market. The 2 prerequisites for future valves may, however,
also be contradictory to each other by replacing one evil with
another: patients that underwent PD in the Hahn et al. (9)
study showed signiﬁcantly less patient–prosthesis-mismatch
(even after multivariable analysis). These data remind us that
making the valve as big as possible is beneﬁcial. This
is an important ﬁndingdeven or particularly in the era
of new valves such as the Edwards SAPIEN 3 (Edwards
Lifesciences, Irvine, California).
How should the study of Hahn et al. (9) change our daily
practice? If the mechanism of PVL is such that PD has a
chance to eliminate the PVL, it should be performed
generously, thereby normalizing the prognosis of the patient.
If we have borderline annulus measurements from the
screening imaging, the relatively low risk of PD allows
for a stepwise enlargement of a balloon-expandable valve
according to its hemodynamic performance: the valve can be
underﬁlled with 1 to 3 ml of contrast and, if needed,
gradually enlarged by adding the respective volume (10).
This technique also allows performing ad-hoc TAVR where
the size of the valve prosthesis is chosen on the basis of a
transthoracic echocardiogram or even a ﬂuoroscopic image.
Also, “softer” parameters should be taken into account, suchas the patient’s height and sex when performing ad-hoc
TAVR. In case of borderline measurements, the bigger-
sized valve is selected, underﬁlled, and if needed, gradually
enlarged by adding some milliliters of saline to the balloon
for PD.With this technique, balloon-expandable TAVR can
be considerably simpliﬁed, while still keeping it a safe pro-
ceduredbut, according to the Hahn et al. (9) data, at the
price of a higher 7-day stroke rate, which is again balanced
out at 30 days.
It must be clearly underlined that transcatheter aortic valve
implantation should aim for perfect outcomes, balancing
safety and efﬁcacy, individualizing the approach by adapting
to patient anatomy, clinical characteristics, and operator
experience. Balloon PD should be done selectively, only
when beneﬁt is expected.
To stay with Winnie: if you have a balloon in your hands
(and you use it wisely) everybody will cheer you!Reprint requests and correspondence: Dr. Fabian Nietlispach,
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